高级检索
    周建娅, 周建英. 帕博利珠单抗联合化疗一线治疗晚期非鳞状非小细胞肺癌:KEYNOTE-021研究G队列长期生存数据[J]. 循证医学, 2021, 21(4): 208-213. DOI: 10.12019/j.issn.1671-5144.2021.04.004
    引用本文: 周建娅, 周建英. 帕博利珠单抗联合化疗一线治疗晚期非鳞状非小细胞肺癌:KEYNOTE-021研究G队列长期生存数据[J]. 循证医学, 2021, 21(4): 208-213. DOI: 10.12019/j.issn.1671-5144.2021.04.004
    shu
    ZHOU Jian-ya, ZHOU Jian-ying. Pembrolizumab With or Without Chemotherapy as First-Line Therapy for Advanced Nonsquamous NSCLC: Comments to Long-Term Overall Survival Data of Cohort G in KEYNOTE-021 Study[J]. Journal of Evidence-Based Medicine, 2021, 21(4): 208-213. DOI: 10.12019/j.issn.1671-5144.2021.04.004
    Citation: ZHOU Jian-ya, ZHOU Jian-ying. Pembrolizumab With or Without Chemotherapy as First-Line Therapy for Advanced Nonsquamous NSCLC: Comments to Long-Term Overall Survival Data of Cohort G in KEYNOTE-021 Study[J]. Journal of Evidence-Based Medicine, 2021, 21(4): 208-213. DOI: 10.12019/j.issn.1671-5144.2021.04.004
    shu

    帕博利珠单抗联合化疗一线治疗晚期非鳞状非小细胞肺癌:KEYNOTE-021研究G队列长期生存数据

    Pembrolizumab With or Without Chemotherapy as First-Line Therapy for Advanced Nonsquamous NSCLC: Comments to Long-Term Overall Survival Data of Cohort G in KEYNOTE-021 Study

      摘要
      • HTML全文
      • 参考文献(11)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回